Naloxone Price Hike May Have Negative Impact on Overdose-Related Deaths

Share this content:
Naloxone Price Hike May Have Negative Impact on Overdose-Related Deaths
Naloxone Price Hike May Have Negative Impact on Overdose-Related Deaths

HealthDay News -- Escalating prices of the drug naloxone may threaten efforts to reduce opioid-related deaths across America, according to a perspective piece published in the New England Journal of Medicine.

The research team from Yale University and the Mayo Clinic called attention to the increasing prices, noting that (1) Hospira (a Pfizer company) charges $142 for a 10-pack of naloxone -- up 129% since 2012; (2) Amphastar's 1 mg version of naloxone is used off-label as a nasal spray. It's priced around $40 -- a 95% increase since September 2014; and (3) newer, easier-to-use formulations are even more expensive -- a 2-dose package of Evzio (naloxone) costs $4,500, an increase of more than 500% over 2 years.

Naloxone is part of a wave of precipitous price hikes affecting old and new medicines. These drugs include Mylan's EpiPen injectors for life-threatening allergic reactions; Turing Pharmaceuticals' Sovaldi for hepatitis C; and insulin for diabetes made by Eli Lilly and Company, Novo Nordisk, and Sanofi US.

Several US agencies have recommended boosting access to naloxone to combat prescription opioid-related deaths, the study authors noted. The authors argued that the government should do more to ensure the drug is affordable. Possible strategies include: encouraging generic competition; buying in bulk; and importing generics from international manufacturers. The government could also invoke a federal law that allows it to contract with a manufacturer to produce less-costly versions, the study authors suggested. It's also possible that the US Food and Drug Administration could switch naloxone to over-the-counter status, the researchers said.

Reference

Gupta R, Shah N, Ross J. The Rising Price of Naloxone — Risks to Efforts to Stem Overdose DeathsN Engl J Med. 2016;375(23):2213-2215. doi:10.1056/nejmp1609578.

You must be a registered member of Neurology Advisor to post a comment.
close

Next Article in Practice Management

Sign Up for Free e-newsletters

CME Focus